Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2‐B3) and thymic carcinoma previously treated with chemotherapy. Issue 4 (27th October 2021)

• Record Type: Journal Article
• Authors: Perrino, Matteo; De Pas, Tommaso; Bozzarelli, Silvia; Giordano, Laura; De Vincenzo, Fabio; Conforti, Fabio; Digiacomo, Nunzio; Cordua, Nadia; D'Antonio, Federica; Borea, Federica; Santoro, Armando; Zucali, Paolo Andrea
• Is Part Of: Cancer. Volume 128:Issue 4(2022)
• Page Start: 719
• Page End: 726
• Publication Date: 2021-10-27
• Subjects: activity -- phase 2 trial -- regorafenib -- thymic epithelial tumors -- toxicity profile; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.33990
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : Background: Angiogenesis has an important role in thymic epithelial tumors (TETs). Regorafenib inhibits vascular endothelial growth factor receptors (VEGFRs), platelet‐derived growth factor receptor β (PDGFR‐β), and fibroblast growth factor receptors (FGFRs). This study explored the activity of regorafenib as monotherapy in patients with advanced or recurrent B2‐B3 thymoma (T) and thymic carcinoma (TC) previously treated with platinum‐containing chemotherapy. Methods: A Fleming single‐arm, single‐stage, phase 2 trial to evaluate the activity of regorafenib (160 mg once a day by mouth for 3 weeks on/1 week off) was planned. The study was designed to reject the null hypothesis of an 8‐week progression‐free survival (PFS) rate ≤25% with a type I error of 0.10 and a statistical power of 80% at the alternative hypothesis of an 8‐week PFS rate of ≥50% (≥8 of 19 evaluable patients progression‐free at 2 months). Results: From June 2016 to November 2017, 19 patients were enrolled (11T/8TC). We observed partial response (PR) in 1 patient (1T) (5.3%), stable disease (SD) in 14 patients (9T/5TC) (73.7%), and progressive disease in 2 patients (1T/1TC) (10.5%), with a disease control rate of 78.9%. According to Choi‐criteria, 13 patients (68.4%) achieved PR, and 2 patients SD (10.5%). The median PFS was 9.6 months whereas median overall survival was 33.8 months. The 8‐week PFS rate was 78.9% (15 of 19 patients). Grade 3‐4 treatment‐related adverse events were observed in 10 patients (52.6%). Conclusions: The primary end point of this study was reached. The high rate of PR (Choi‐criteria) suggests antitumor activity of regorafenib in TETs. On the basis of survival outcomes, the efficacy of regorafenib should be further evaluated in larger studies. Abstract : The results of the activity and toxicity profile of regorafenib observed in this small series of thymic epithelial tumors are encouraging and should be better evaluated in subsequent larger and specific study phases.